Back to top
more

Avalo Therapeutics (AVTX)

(Delayed Data from NSDQ)

$15.94 USD

15.94
78,216

+0.96 (6.41%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.37 -0.57 (-3.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why

by Zacks Equity Research

Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.

Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 27.85% and 17.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

New Strong Buy Stocks for January 3rd

by Zacks Equity Research

GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.

New Strong Buy Stocks for December 14th

by Zacks Equity Research

MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.

Travere (TVTX) Up on Latest Portfolio Updates & Reorganization

by Zacks Equity Research

Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.

ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA

by Zacks Equity Research

The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.

New Strong Buy Stocks for November 27th

by Zacks Equity Research

VVI, AVTX, RYI, TM and HIBB have been added to the Zacks Rank #1 (Strong Buy) List on November 27, 2023.

New Strong Buy Stocks for November 21st

by Zacks Equity Research

AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.

Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs

by Zacks Equity Research

Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.

Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 34.44% and 35.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%

by Zacks Equity Research

Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.

Avalo Therapeutics, Inc. (AVTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 12.37% and 52.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Avalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review

by Zacks Equity Research

The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.

Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal

by Zacks Equity Research

Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.

Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device

by Zacks Equity Research

Roche (RHHBY) and Lilly announce a collaboration deal to support the development of the former's early diagnosis device for Alzheimer's Disease.

Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

by Zacks Equity Research

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.

ACER's Stock Down on Failure of Phase II Study, Cash Updates

by Zacks Equity Research

ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote

by Zacks Equity Research

FDA's Antimicrobial Drugs Advisory Committee (AMDAC) votes 16 to 1 for Pfizer's Paxlovid for the treatment of mild-to-moderate COVID-19 in adult patients at high risk of hospitalization or death.

Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of -5.33% and 81.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Avalo Therapeutics (AVTX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Avalo Therapeutics (AVTX) stock based on the movements in the options market lately.

Wall Street Analysts Predict a 191% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 191.3% in Avalo Therapeutics, Inc. (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.